Jenburkt Pharmaceuticals Ltd (JENBURPH) is currently trading at 860.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Jenburkt Pharmaceuticals Ltd is a company engaged in the manufacturing and marketing of pharmaceutical formulations and healthcare products both in India and internationally. The company operates a manufacturing plant in Gujarat that complies with WHO guidelines, demonstrating its commitment to quality and global standards. Jenburkt has a vast distribution network of over 1,000 stockists, extending its reach to more than 400,000 pharmacies globally. In recent years, the company diversified into the OTC market with the launch of its Jenburkt Wellness division, introducing products like Zixa Strong and Nervijen D3.

Over the past 52 weeks, Jenburkt Pharmaceuticals Ltd has traded between a low of ₹852.00 and a high of ₹1,321.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Jenburkt Pharmaceuticals Ltd has a market capitalization of approximately 379.54. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Jenburkt Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 11.56 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 379.54 Cr, Jenburkt Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Jenburkt Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Jenburkt Pharmaceuticals Ltd is 11.56. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Shareholders approved a final dividend of ₹20.70 per equity share for FY26, described by the company as 207% on the ₹10 face value.

The 41st AGM is scheduled for Friday, September 4, 2026, at 3:30 p.m. IST, and will be held via VC/OAVM.